See also this year's filing and all EDGAR filings for this company.
PDF Report 0000810509_2021_Navidea_Biopharmaceuticals_Inc.pdf
Logs
| warning | The stock price does not exist | industry.us_generic | {} |
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Revenues', 'missing_ratio': 0.0007238229886181185, 'aggregate_val': 531513, 'exp_sum': 531898, 'exp_to_value': {'remainder_Revenues': 531898}} |
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Revenues', 'missing_ratio': 0.00030045187962695897, 'aggregate_val': 915013, 'exp_sum': 915288, 'exp_to_value': {'remainder_Revenues': 915288}} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('0000810509')"} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0000810509, Navidea Biopharmaceuticals Inc
| xvar | xval | |
|---|---|---|
| 0 | LiabilitiesNoncurrent | 296,006 |
| 1 | LiabilitiesCurrent | 4,715,105 |
| 2 | remainder_Liabilities | 700,000 |
| 3 | AssetsCurrent | 6,528,328 |
| 4 | AssetsNoncurrent | 477,287 |
| 5 | PropertyPlantAndEquipmentNet | 132,162 |
| 6 | Goodwill | 620,241 |
| 7 | remainder_Assets | 0 |
| 8 | GeneralAndAdministrativeExpense | 6,696,007 |
| 9 | ResearchAndDevelopmentExpense | 4,930,187 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 915,013 |
| 12 | remainder_NetIncome | -10,510 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Liabilities | 5,711,111 |
| 1 | Assets | 7,758,018 |
| 2 | Expenses | 11,626,194 |
| 3 | Revenues | 915,013 |
| 4 | StockholdersEquity | 2,046,907 |
| 5 | NetIncome | -10,721,691 |
| 6 | ComprehensiveNetIncome | -10,721,691 |
| 7 | BaseVar | 13,010,423 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | -1.18 |
| 9 | EconomicCapitalRatio | 0.622 |
Edgar->Model Mapping
Feature Distribution
Change over Time
